Celularity Inc. Files Form 8-K: Key Points for Investors

Overview

Celularity Inc., a biotechnology company headquartered at 170 Park Ave, Florham Park, NJ 07932, has filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC). The filing date and the date of the earliest event reported is February 27, 2026. The company’s shares are listed under the trading symbol CELU on the Nasdaq Stock Market LLC. This report is an important regulatory filing under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Key Points in the Report

• Form 8-K Filed: The document is a current report (Form 8-K), which is typically used to announce major events that shareholders should know about.
• Security Listings:
  • Class A Common Stock, \$0.0001 Par Value Per Share: Trading Symbol: CELU, listed on Nasdaq Stock Market LLC.
  • Warrants: Each warrant is exercisable for one-tenth of one share of Class A Common Stock at an exercise price of \$11.50 per share. Trading Symbol: CELUW, also listed on Nasdaq Stock Market LLC.
• Emerging Growth Company: Celularity Inc. has indicated it is an Emerging Growth Company, meaning it may be subject to reduced regulatory and reporting requirements.
• Transition Period: The company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
• Filing Checkboxes: The company confirmed via checkboxes that this 8-K is NOT intended to satisfy the filing obligations under any of the following:
  • Written communications under Rule 425
  • Soliciting material under Rule 14a-12
  • Pre-commencement communications under Rule 14d-2(b) or 13e-4(c)
• No Details on Material Events: The Form 8-K cover and attached XBRL files do not disclose any specific material event, transaction, or change (such as mergers, acquisitions, leadership changes, or financial restatements) that would be price-sensitive or significantly impact shareholder value at this time.

What Shareholders Should Know

• No Price-Sensitive News Disclosed: Based on the content of the filing, there are no disclosures of events or corporate actions that are likely to immediately affect the share price or indicate a change in the company’s financial or strategic position.
• Routine Compliance Filing: This appears to be a routine regulatory filing, likely to maintain compliance with SEC requirements for ongoing disclosure and transparency.
• Warrants Structure: Investors holding or considering purchasing the company’s warrants should note their structure – each warrant is for one-tenth of a share at \$11.50 per share, which may affect their value and exercise dynamics.

Conclusion

There are no new, material, or price-sensitive announcements in this Form 8-K filing from Celularity Inc. that would likely impact the share value at this time. The filing serves primarily as a compliance and administrative update.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should consult official SEC filings and their financial advisors before making any investment decisions. The information herein is based solely on the disclosed Form 8-K and associated materials as provided.

View Celularity Inc Historical chart here